This website is intended for UK healthcare professionals only and contains promotional content.

Report an adverse event here
United Kingdom - English

United Kingdom - English

United Kingdom | English

These country specific websites are specifically intended for healthcare professionals in listed countries only.

Europe

Deutschland - DeutschDeutschland - Deutsch España - EspañolEspaña - Español Italia - ItalianoItalia - Italiano United Kingdom - EnglishUnited Kingdom - English

NOTICE:Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on the following pages, including but not limited to these Established Medicines. For more information please click here.​

Our Products

Grünenthal Meds provides treatments for patients suffering with a range of conditions, including opioid-induced constipation, chronic anal fissure, breakthrough cancer pain, chemotherapy-induced nausea and vomiting, vitamin D deficiency and vitamin B & C deficiencies.

Click on the links below to learn more about these conditions and the ways in which we can help you treat them.

Adverse Events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk/. Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email PVUK@grunenthalmeds.com

Bone Health

Vitamin D Deficiency

Provided by
KKI NewCo (known as Grünenthal Meds)

Stexerol-D3 is indicated in adults, the elderly and adolescents for prevention and treatment of vitamin D deficiency, or as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency.1

Click here for prescribing and adverse event reporting information.

LEARN MORE

Gastrointestinal

OPIOID-INDUCED CONSTIPATION

Provided by
KKI NewCo (known as Grünenthal Meds)

MOVENTIG is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).2

Click here for prescribing and adverse event reporting information.

LEARN MORE

CHRONIC ANAL FISSURE

Provided by
KKI NewCo (known as Grünenthal Meds)

RECTOGESIC® 4 mg/g Rectal Ointment is indicated in adults for relief of pain associated with chronic anal fissure.3

Click here for prescribing and adverse event reporting information.

LEARN MORE

Oncology

Responsible Usage
Grünenthal Meds supports the responsible use of opioids. Not all medicines containing opioids are authorised for all types of pain indication. Please refer to the specific Summary of Product Characteristics before prescribing. For advice on the responsible use of opioids, including those indicated for other types of pain, please click here.

BREAKTHROUGH CANCER PAIN

Provided by
KKI NewCo (known as Grünenthal Meds)

Abstral® is indicated for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.4

Click here for prescribing and adverse event reporting information.

Click here for risk materials.

LEARN MORE

BREAKTHROUGH CANCER PAIN

Provided by
KKI NewCo (known as Grünenthal Meds)

PecFent® is indicated for the management of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.5

Click here for prescribing and adverse event reporting information.

Click here for risk materials.

LEARN MORE

Chemotherapy-induced Nausea and Vomiting

Provided by
KKI NewCo (known as Grünenthal Meds)

SANCUSO® transdermal patch is indicated in adults for the prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy, for a planned duration of 3 to 5 consecutive days, where oral anti-emetic administration is complicated by factors making swallowing difficult.6

Click here for prescribing and adverse event reporting information.

LEARN MORE

Average:

  • References

    1. Stexerol-D3® (colecalciferol) Summary of Product Characteristics.

    2. MOVENTIG® (naloxegol) Summary of Product Characteristics.

    3. RECTOGESIC® (glyceryl trinitrate) Summary of Product Characteristics.

    4. Abstral® (fentanyl citrate) Summary of Product Characteristics.

    5. PecFent® (fentanyl citrate) Summary of Product Characteristics.

    6. SANCUSO® (granisetron) Summary of Product Characteristics.

    M-GRM-HQ-11-24-0007 June 2025

This website is for healthcare professionals only.

If you are a registered healthcare professional outside the UK please visit the Grünenthal Meds Website

M-GRM-HQ-11-24-0006 May 2025